Frontiers in Oncology (Nov 2022)

Metabolism-associated molecular classification of gastric adenocarcinoma

  • Yuqing Ye,
  • Wenyun Yang,
  • Xinjia Ruan,
  • Li Xu,
  • Wenxuan Cheng,
  • Mengmeng Zhao,
  • Xin Wang,
  • Xinyi Chen,
  • Daren Cai,
  • Guanjie Li,
  • Yuhang Wang,
  • Fangrong Yan,
  • Xiaofan Lu,
  • Xiaofan Lu,
  • Liyun Jiang

DOI
https://doi.org/10.3389/fonc.2022.1024985
Journal volume & issue
Vol. 12

Abstract

Read online

Most gastric cancers (GC) are adenocarcinomas, whereas GC is a highly heterogeneous disease due to its molecular heterogeneity. However, traditional morphology-based classification systems, including the WHO classification and Lauren’s classification, have limited utility in guiding clinical treatment. We performed nonnegative matrix factorization (NMF) clustering based on 2752 metabolism-associated genes. We characterized each of the subclasses from multiple angles, including subclass-associated metabolism signatures, immune cell infiltration, clinic10al characteristics, drug sensitivity, and pathway enrichment. As a result, four subtypes were identified: immune suppressed, metabolic, mesenchymal/immune exhausted and hypermutated. The subtypes exhibited significant prognostic differences, which suggests that the metabolism-related classification has clinical significance. Metabolic and hypermutated subtypes have better overall survival, and the hypermutated subtype is likely to be sensitive to anti-PD-1 immunotherapy. In addition, our work showed a strong connection with previously established classifications, especially Lei’s subtype, to which we provided an interpretation based on the immune cell infiltration perspective, deepening the understanding of GC heterogeneity. Finally, a 120-gene classifier was generated to determine the GC classification, and a 10-gene prognostic model was developed for survival time prediction.

Keywords